Shell Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Shell Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$178K	Sell	9,022 -11,675	-56%	-$240K	0.02%	500
2025 Q2	$449K	Sell	20,697 -3,654	-15%	-$86.3K	0.02%	511
2025 Q1	$591K	Sell	24,351 -1,012	-4%	-$22.8K	0.03%	414
2024 Q4	$529K	Sell	25,363 -33	-0.1%	-$709	0.02%	477
2024 Q3	$505K	Buy	+25,396	New	+$471K	0.02%	485
2024 Q1	$448K	Sell	28,896 -2,884	-9%	-$43.5K	0.02%	510
2023 Q4	$534K	Sell	31,780 -9,540	-23%	-$130K	0.02%	493
2023 Q3	$483K	Sell	41,320 -6,755	-14%	-$90.4K	0.02%	578
2023 Q2	$646K	Sell	48,075 -2,906	-6%	-$41.8K	0.03%	492
2023 Q1	$845K	Sell	50,981 -177	-0.3%	-$2.92K	0.04%	401
2022 Q4	$952K	Sell	51,158 -10,663	-17%	-$164K	0.04%	372
2022 Q3	$793K	Sell	61,821 -16,198	-21%	-$192K	0.03%	414
2022 Q2	$547K	Buy	78,019 +133	+0.2%	+$976	0.02%	666
2022 Q1	$646K	Sell	77,886 -11,521	-13%	-$81.5K	0.02%	681
2021 Q4	$605K	Buy	89,407 +417	+0.5%	+$2.74K	0.01%	808
2021 Q3	$472K	Sell	88,990 -3,820	-4%	-$20.9K	0.01%	893
2021 Q2	$534K	Buy	92,810 +37,411	+68%	+$193K	0.01%	881
2021 Q1	$255K	Buy	+55,399	New	+$220K	0.01%	1084

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Shell Asset Management's CPRX Position: Q3 2025 in Review

Shell Asset Management reduced its Catalyst Pharmaceutical (CPRX) stake by 56% in Q3 2025, selling an estimated $240K and leaving 9,022 shares worth $178K. The position accounts for 0.02% of the portfolio, ranked #500.

Shell Asset Management first reported a position in CPRX in Q1 2021 and has held it in 18 quarters since. The position peaked at $952K in Q4 2022. 360 funds tracked by Wall St. Rank hold CPRX as of Q3 2025.

Shell Asset Management held 9,022 shares of Catalyst Pharmaceutical worth $178K as of Q3 2025.
Shell Asset Management sold 11,675 Catalyst Pharmaceutical shares in Q3 2025, an estimated $240K.
Catalyst Pharmaceutical made up 0.02% of Shell Asset Management's portfolio in Q3 2025, its #500 holding.
Shell Asset Management first reported a position in Catalyst Pharmaceutical in Q1 2021 and has held it in 18 quarters since.
Shell Asset Management's Catalyst Pharmaceutical position peaked at $952K in Q4 2022.
360 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2025.

Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.